Boothbay Fund Management, LLC Neurocrine Biosciences Inc Transaction History

Boothbay Fund Management, LLC

$3.6 Billion
Q3 2024

A detailed history of Boothbay Fund Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 2,337 shares of NBIX stock, worth $296,214. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,337

Previous 30,300 92.29%

Holding current value

$296,214

Previous $4.17 Million 93.55%

% of portfolio

0.01%

Previous 0.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $1.03 Million - $1.38 Million	-8,983 Reduced 79.36%	2,337 $269,000
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $1.48 Million - $1.62 Million	11,320 New	11,320 $1.56 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $3.45 Million - $4.51 Million	36,624 New	36,624 $3.71 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $985,194 - $1.3 Million	-12,999 Reduced 75.26%	4,273 $417,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $1.13 Million - $1.51 Million	14,233 Added 468.34%	17,272 $1.47 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $33,868 - $38,918	-393 Reduced 11.45%	3,039 $291,000
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $306,923 - $350,990	3,432 New	3,432 $334,000
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $2.53 Million - $3.45 Million	-29,100 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $2.44 Million - $2.95 Million	29,100 New	29,100 $2.62 Million
Q1 2018 May 14, 2018	SELL	$75.88 - $92.43 $317,937 - $387,281	-4,190 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $245,240 - $325,102	4,190	4,190 $325,000

Others Institutions Holding NBIX

# of Institutions

627

Shares Held

94.3M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Account

Boothbay Fund Management, LLC Neurocrine Biosciences Inc Transaction History